MDS Beacon News Flashes - 5/14/12

[Sally C]

Beacon NewsFlashes - May 14, 2012
by Maike Haehle

FDA Announces Update About Revlimid And Second Cancers – The U.S. Food and Drug Administration (FDA) issued an extensive update last week regarding the risk of developing a second cancer while being treated with Revlimid (lenalidomide).

Onconova Announces Phase 2 Clinical Trial Of Oral Estybon In MDS – Onconova Therapeutics last week announced the start of a Phase 2 clinical trial of its investigational drug Estybon (rigosertib, ON 01910.Na) in MDS.

Living With MDS Conference For Patients And Families – The Aplastic Anemia and MDS International Foundation (AA&MDSIF) will hold a free, one-day conference about living with MDS in Atlanta on May 19.

For the details, see the NewsFlashes at MDS Beacon.

[Jun]

Rigosertib has being prepared to initiate a Phase I clinical trial for the treatment of MDS in Japan, too.
We are exited to expect to have :excellent results!